This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AAT, Inhaled Alpha 1-Antitrypsin
BioMedTracker maintains separate drug profiles for the inhaled (IH) and intravenous (IV) formulations of Alpha 1-Antitrypsin (AAT).
AAT is a proprietary compound targeting the protease inhibitor A1AT.
Kamada and Chiesi
In August 2012, Kamada announced it has entered into an exclusive distribution agreement with Chiesi for the distribution of its breakthrough inhaled alpha-1 antitrypsin for treatment of alpha-1 antitrypsin deficiency (AATD-IH). Under the terms of the agreement, Kamada will receive milestone payments of $60 million, subject to achievement of certain regulatory and sales targets. In addition, Chiesi is committed to minimum purchases tens of millions USD during the first 5 years following the acceptance of the required regulatory approvals. The agreement is for 12 years.
According to the agreement, Chiesi will be responsible for the distribution of Kamada's AATD-IH product in Europe, Turkey and former CIS countries including promoting the drug, identifying patients and handling reimbursements. Kamada retains all rights in its AAT-IV products or other AAT-IH indications products and it was agreed that both companies will examine additional...See full deal structure in Biomedtracker
Partners: Chiesi Farmaceutici S.p.A.
AAT (IH) News
Additional information available to subscribers only: